Surbhi Bansal1, S Asha Balakrishnan1, Taylor Blachley1, Jennifer S Weizer1, Paul P Lee2, Joshua D Stein3. 1. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan. 2. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 3. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Electronic address: jdstein@med.umich.edu.
Abstract
PURPOSE: To evaluate use of medical, laser, or incisional surgical interventions for glaucoma after laser peripheral iridotomy (LPI). DESIGN: Retrospective longitudinal cohort study. METHODS: All enrollees aged ≥21 years in a US managed-care network who underwent bilateral LPIs in 2001-2011 were identified. The mean numbers of pre- and post-LPI glaucoma medication classes prescribed and the proportion of enrollees requiring cataract or glaucoma surgery within 2 years after the LPIs were determined. Multivariable logistic regression assessed factors associated with enrollees' prescription of ≥1 glaucoma medication class after bilateral LPIs. RESULTS: Of the 1660 patients undergoing bilateral LPIs, 1280 (77.1%) had no pre- or post-LPI prescriptions for any glaucoma medication class. Of the remaining patients, 251 (66.1%) required more glaucoma medication classes after than before the procedures, whereas 44 (11.6%) used fewer after the procedures; 85 (22.4%) were prescribed the same number before and after the LPIs. A total of 167 patients (10.1%) underwent cataract surgery and 79 (4.8%) received glaucoma surgery over the 2-year follow-up. Black patients had a 130% increased odds for glaucoma medication-class prescriptions after bilateral LPIs, compared with white patients (P = .02). The odds of post-LPI glaucoma medication use increased by 21% for every additional 5 years of age (P < .0001). CONCLUSION: Most patients undergoing bilateral LPIs received no pre- or post-LPI glaucoma medication-class prescriptions and had no cataract or additional glaucoma surgery within 2 years after LPIs. Clinicians should alert black or older patients and those already taking glaucoma medications before the procedure of their higher odds of requiring medications afterward.
PURPOSE: To evaluate use of medical, laser, or incisional surgical interventions for glaucoma after laser peripheral iridotomy (LPI). DESIGN: Retrospective longitudinal cohort study. METHODS: All enrollees aged ≥21 years in a US managed-care network who underwent bilateral LPIs in 2001-2011 were identified. The mean numbers of pre- and post-LPIglaucoma medication classes prescribed and the proportion of enrollees requiring cataract or glaucoma surgery within 2 years after the LPIs were determined. Multivariable logistic regression assessed factors associated with enrollees' prescription of ≥1 glaucoma medication class after bilateral LPIs. RESULTS: Of the 1660 patients undergoing bilateral LPIs, 1280 (77.1%) had no pre- or post-LPI prescriptions for any glaucoma medication class. Of the remaining patients, 251 (66.1%) required more glaucoma medication classes after than before the procedures, whereas 44 (11.6%) used fewer after the procedures; 85 (22.4%) were prescribed the same number before and after the LPIs. A total of 167 patients (10.1%) underwent cataract surgery and 79 (4.8%) received glaucoma surgery over the 2-year follow-up. Black patients had a 130% increased odds for glaucoma medication-class prescriptions after bilateral LPIs, compared with white patients (P = .02). The odds of post-LPIglaucoma medication use increased by 21% for every additional 5 years of age (P < .0001). CONCLUSION: Most patients undergoing bilateral LPIs received no pre- or post-LPIglaucoma medication-class prescriptions and had no cataract or additional glaucoma surgery within 2 years after LPIs. Clinicians should alert black or older patients and those already taking glaucoma medications before the procedure of their higher odds of requiring medications afterward.
Authors: Mohamad Rosman; Tin Aung; Leonard P K Ang; Paul T K Chew; Jeffrey M Liebmann; Robert Ritch Journal: Ophthalmology Date: 2002-12 Impact factor: 12.079
Authors: J L Y Yip; W P Nolan; C E Gilbert; D Uranchimeg; J Baassanhuu; P S Lee; P T Khaw; G J Johnson; P J Foster Journal: Eye (Lond) Date: 2010-06-11 Impact factor: 3.775
Authors: Ce Zheng; Celeste P Guzman; Carol Y Cheung; Yingke He; David S Friedman; Sim-Heng Ong; Arun K Narayanaswamy; Paul T Chew; Shamira A Perera; Tin Aung Journal: JAMA Ophthalmol Date: 2013-01 Impact factor: 7.389
Authors: Roland Y Lee; Toshimitsu Kasuga; Qi N Cui; Guofu Huang; Mingguang He; Shan C Lin Journal: Invest Ophthalmol Vis Sci Date: 2013-05-01 Impact factor: 4.799